As an early pioneer of microbiome science, OpenBiome has changed the landscape of healthcare. Microbiome-based therapies are a new frontier of medicine that present a promising option for patients who have exhausted standard treatments. Since 2012, OpenBiome has provided more than 65,000 investigational fecal microbiota transplantation (FMT) preparations for patients with antibiotic-resistant C. difficile.

 

I developed, launched, and scaled the full drug product life cycle of an oral version of Openbiome's therapy, including wet-lab experiments, execution of go-to-market plans, and internal organizational preparedness.

​

​

​

To learn more about poop pills, reach out!